Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.

ABSTRACT:

Background

The chemotherapeutic agent 5-fluorouracil (5-FU) is catabolized by dihydropyrimidine dehydrogenase (DPD), the deficiency of which may lead to severe toxicity or death. Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens. However, it has been recently shown that renal impairment may impact uracil concentration and thus DPD phenotyping.

Patients and methods

The impact of renal function on uracilemia and DPD phenotype was studied on 3039 samples obtained from three French centers. We also explored the influence of dialysis and measured glomerular filtration rate (mGFR) on both parameters. Finally, using patients as their own controls, we assessed as to what extent

SUBMITTER: Royer B 

PROVIDER: S-EPMC10265596 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature